Prognostic and predictive values of the immunoscore in patients with rectal cancer

Clinical Cancer Research

Volumn 20, Issue 7, 2014, Pages 1891-1899

  Anitei, Maria Gabriela ^a,b   Zeitoun, Guy ^d   Mlecnik, Bernhard ^e   Marliot, Florence ^d,e,f   Haicheur, Nacilla ^d   Todosi, Ana Maria ^a   Kirilovsky, Amos ^e   Lagorce, Christine ^h   Bindea, Gabriela ^e   Ferariu, Dan ^b   Danciu, Mihai ^a,c   Bruneval, Patrick ^d,f   Scripcariu, Viorel ^a,b   Chevallier, Jean Marc ^d,f   Zinzindohoué, Franck ^d,f   Berger, Anne ^d,f   Galon, Jérôme ^e,g   Pagès, Franck ^d,e,f  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b REGIONAL INSTITUTE OF ONCOLOGY   (Romania)

^c University Hospital Sf Spiridon   (Romania)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e INSERM   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g SORBONNE UNIVERSITÉ   (France)

^h AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHEMORADIOTHERAPY; COMPUTER PROGRAM; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOSCORE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MESORECTUM EXCISION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RECTUM CANCER; SCORING SYSTEM; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR RECURRENCE; VERY ELDERLY; BIOPSY; FEMALE; IMMUNOLOGY; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; RADIATION DOSE; RECTAL NEOPLASMS; TREATMENT OUTCOME;

CD3 ANTIGEN;

AGED; AGED, 80 AND OVER; ANTIGENS, CD3; BIOPSY; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84898714462     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2830     Document Type: Article

References (38)

1. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
2. Nagtegaal ID, Quirke P, Schmoll HJ. Has the new TNM classification for colorectal cancer improved care? Nat Rev Clin Oncol 2011;9:119-123.
3. Deschoolmeester V, Baay M, Specenier P, Lardon F, Vermorken JB. A reviewof the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist 2010;15:699-731.
4. Benson AB3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, et al. Rectal cancer. J Natl Compr Canc Netw 2012;10:1528-64.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
6. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298-306.
7. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4. (Pubitemid 44498003)
8. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011;29:610-618.
9. Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012;10:1.
10. Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, et al. Cancer classification using the immunoscore: a worldwide task force. J Transl Med 2012;10:205.
11. Delattre O, Olschwang S, Law DJ, Melot T, Remvikos Y, Salmon RJ, et al. Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 1989;2:353-6. (Pubitemid 19189066)
12. Li M, Li JY, Zhao AL, Gu J. Colorectal cancer or colon and rectal cancer? Clinicopathological comparison between colonic and rectal carcinomas. Oncology 2007;73:52- 57.
13. Azzoni C, Bottarelli L, Campanini N, Di Cola G, Bader G, Mazzeo A, et al. Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the tumorigenesis. Int J Colorectal Dis 2007;22:115-26. (Pubitemid 44964014)
14. MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet 1993;341:457-60. (Pubitemid 23054519)
15. Mlecnik B, Sanchez-Cabo F, Charoentong P, Bindea G, Pagès F, Berger A, et al. Data integration and exploration for the identification of molecular mechanisms in tumor immune cells interaction. BMC Genomics 2010;11:S7.
16. Petrelli F, Borgonovo K, Barni S. The emerging issue of ratio of metastatic to resected lymph nodes in gastrointestinal cancers: an overview of literature. Eur J Surg Oncol 2011;37:836-47.
17. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654-66. (Pubitemid 41817714)
18. Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 2005;47:141-6. (Pubitemid 41113116)
19. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86:829-35. (Pubitemid 2100935)
20. Holländer N, Sauerbrei W, Schumacher M. Confidence intervals for the effect of a prognostic factor after selection of an 'optimal' cutpoint. Stat Med 2004;23:1701-13. (Pubitemid 38765340)
21. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40.
22. Frey B, Stache C, Rubner Y, Werthmöller N, Schulz K, Sieber R, et al. Combined treatment of human colorectal tumor cell lines with chemotherapeutic agents and ionizing irradiation can in vitro induce tumor cell death forms with immunogenic potential. J Immunotoxicol 2012;9:301-13.
23. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-81.
24. Kosinski L, Habr-Gama A, Ludwig K, Perez R. Shifting concepts in rectal cancer management: a review of contemporary primary rectal cancer treatment strategies. CA Cancer J Clin 2012;62:173-202.
25. Sadahiro S, Suzuki T, Ishikawa K, Nakamura T, Tanaka Y, Masuda T, et al. Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years. Hepatogastroenterology 2003;50:1362-6. (Pubitemid 37186484)
26. Påhlman L, Bohe M, Cedermark B, Dahlberg M, Lindmark G, Sjödahl R, et al. The Swedish rectal cancer registry. Br J Surg 2007;94:1285-92. (Pubitemid 47584780)
27. Ceelen WP. Progress in rectal cancer treatment. ISRN Gastroenterol 2012;2012:648183.
28. Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F, et al. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 2009;10:877-84.
29. Deschoolmeester V, Baay M, Van Marck E, Weyler J, Vermeulen P, Lardon F, et al. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol 2010;11:19.
30. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010;222:350-66.
31. Lugli A, Karamitopoulou E, Panayiotides I, Karakitsos P, Rallis G, Peros G, et al. CD8 +lymphocytes/tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer. Br J Cancer 2009:101:1382-92.
32. Jass JR. Lymphocytic infi ltration and survival in rectal cancer. J Clin Pathol 1986;39:585-9. (Pubitemid 16069660)
33. Szynglarewicz B, Matkowski R, Suder E, Sydor D, Forgacz J, Pudeøko M, et al. Predictive value of lymphocytic infiltration and character of invasive margin following total mesorectal excision with sphincter preservation for the high-risk carcinoma of the rectum. Adv Med Sci 2007;52:159-163.
34. Nagtegaal ID, Marijnen CA, Kranenbarg EK, Mulder-Stapel A, Hermans J, van de Velde CJ, et al. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect-a histopathological and immunohistochemical study. BMC Cancer 2001;1:7.
35. Dukes CE. The surgical pathology of rectal cancer. J Clin Pathol 1949;2:95-98.
36. Yasuda K, Nirei T, Sunami E, Nagawa H, Kitayama J. Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer. Radiat Oncol 2011;6:49.
37. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013;39:74 -88.
38. Casado E, García VM, Sánchez JJ, Blanco M, Maurel J, Feliu J, et al. A combined strategy of SAGE and quantitative PCR Provides a 13-gene signature that predicts preoperative chemoradiotherapy response and outcome in rectal cancer. Clin Cancer Res 2011;17:4145-54.